Latest News and Press Releases

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies

Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients...

Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as...

Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as ChairFunding recognises Harness’...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.

Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...

THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration

Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...